Ray Dalio Bridgewater Associates
Ray Dalio is the founder of Bridgewater Associates, one of the world’s largest hedge funds, known for its unique “principles-based” culture and systematic investment approach. Dalio’s investment philosophy emphasizes diversified portfolios, risk parity, and the importance of understanding economic cycles in shaping investment decisions. He has authored several books, including “Principles: Life & Work,” in which he details his management philosophies, personal experiences, and life lessons.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$505M |
| 2 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$443M |
| 3 |
Alibaba
BABA
|
+$370M |
| 4 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$284M |
| 5 |
Procter & Gamble
PG
|
+$256M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lowe's Companies
LOW
|
+$40M |
| 2 |
Home Depot
HD
|
+$38.9M |
| 3 |
JD.com
JD
|
+$35.3M |
| 4 |
SPDR Gold Trust
GLD
|
+$31.6M |
| 5 |
Tesla
TSLA
|
+$26.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Staples | 25.83% |
| 2 | Healthcare | 17.87% |
| 3 | Consumer Discretionary | 13.79% |
| 4 | Technology | 4.61% |
| 5 | Financials | 4.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
iShares MSCI Taiwan ETF
EWT
$10.7B
| $85.7M | 0.35% |
1,393,923
-32,835
| -2% | -$2.1M |
|
52
Monster Beverage
MNST
$88.4B
| $84.4M | 0.34% |
2,113,414
+519,328
| +33% | +$21.8M |
|
53
Veeva Systems
VEEV
$37.4B
| $82.6M | 0.33% |
388,550
+98,451
| +34% | +$21.4M |
|
54
General Mills
GIS
$19.7B
| $82.1M | 0.33% |
1,212,432
+623,098
| +106% | +$41.8M |
|
55
Thermo Fisher Scientific
TMO
$220B
| $80.2M | 0.32% |
135,749
+89,233
| +192% | +$51.3M |
|
56
McKesson
MCK
$101B
| $78.6M | 0.32% |
256,689
+77,553
| +43% | +$21.1M |
|
57
Tyson Foods
TSN
$20.4B
| $78.4M | 0.32% |
874,290
+241,799
| +38% | +$22M |
|
58
iShares MSCI China ETF
MCHI
$6.38B
| $76.9M | 0.31% |
1,453,428
+185,839
| +15% | +$10.9M |
|
59
Idexx Laboratories
IDXX
$46.2B
| $76.3M | 0.31% |
139,441
+35,770
| +35% | +$18.8M |
|
60
DexCom
DXCM
$32B
| $74.3M | 0.3% |
580,964
+154,828
| +36% | +$16.9M |
|
61
RTX Corp
RTX
$301B
| $74.2M | 0.3% |
748,866
+562,634
| +302% | +$53.3M |
|
62
Baxter International
BAX
$14.2B
| $73.6M | 0.3% |
948,766
+295,605
| +45% | +$24.8M |
|
|
ONC
63
BeOne Medicines Ltd
ONC
$38.7B
| $72.4M | 0.29% |
383,818
+154,335
| +67% | +$32.8M |
|
64
Accenture
ACN
$108B
| $71.2M | 0.29% |
211,086
+119,970
| +132% | +$40.5M |
|
65
Eli Lilly
LLY
$1.06T
| $70.8M | 0.29% |
247,346
+124,227
| +101% | +$32M |
|
66
Chevron
CVX
$366B
| $70.7M | 0.29% |
434,365
+429,308
| +8,489% | +$61.6M |
|
67
Brown-Forman Class B
BF.B
$13.1B
| $70.7M | 0.29% |
1,055,285
+340,532
| +48% | +$22.7M |
|
68
Church & Dwight Co
CHD
$24.5B
| $70.6M | 0.28% |
710,060
+172,787
| +32% | +$17.2M |
|
69
Yum China
YUMC
$16.3B
| $67.5M | 0.27% |
1,624,759
+536,447
| +49% | +$25.3M |
|
70
ResMed
RMD
$30.7B
| $65.7M | 0.26% |
270,790
+83,388
| +44% | +$20.2M |
|
|
CERN
71
DELISTED
Cerner Corp
CERN
| $65.6M | 0.26% |
701,671
+87,665
| +14% | +$8.11M |
|
72
iShares MBS ETF
MBB
$39.1B
| $65.6M | 0.26% |
+644,100
| New | +$67.2M |
|
73
JPMorgan Chase
JPM
$950B
| $65.4M | 0.26% |
479,460
+216,411
| +82% | +$31.9M |
|
74
Merck
MRK
$318B
| $64.3M | 0.26% |
784,070
+393,728
| +101% | +$31M |
|
75
XPeng
XPEV
$11.6B
| $59.4M | 0.24% |
2,153,216
+1,083,108
| +101% | +$38.4M |
|
Similar funds
Ray Dalio's Q1 2022 Portfolio in Review
As of Q1 2022, Ray Dalio held 991 positions worth $24.8B, up 44% from $17.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Ray Dalio deployed $8.89B of net new capital in Q1 2022, opening 260 new positions and adding to 547 existing holdings. Its largest new stake was Medtronic: 1,880,088 shares worth $209M.
By sector, the portfolio is most concentrated in Consumer Staples at 26% of assets, down from 28% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was Lowe's Companies, an estimated $40M trimmed.
- Ray Dalio's largest Q1 2022 buy was Medtronic: 1,880,088 shares worth $209M.
- Ray Dalio added most to iShares MSCI Emerging Markets ETF in Q1 2022, an estimated $505M increase.
- Ray Dalio's biggest Q1 2022 reduction was Lowe's Companies, cutting an estimated $40M.
- Ray Dalio fully exited Tesla in Q1 2022, selling an estimated $26.9M.
- Ray Dalio's ten largest holdings make up 34% of its $24.8B portfolio in Q1 2022.
- Ray Dalio opened 260 new positions and closed 23 in Q1 2022.
- Ray Dalio's portfolio value rose 44% quarter-over-quarter to $24.8B.
Based on Bridgewater Associates's 13F filing for Q1 2022, filed 13 May 2022.